NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a major upgrade to
the Quell Wearable Pain Relief technology has started shipping to
consumers and healthcare providers. The latest version of the company’s
over-the-counter, 100% drug free chronic pain relief wearable received a
510(k) clearance (K152954) from the U.S. Food and Drug
Administration (FDA) in January 2016. The Quell device is now more fully
integrated with the Quell Relief smartphone app to provide an
unprecedented level of convenience and comfort for people using Quell to
treat chronic pain. With the recently released update to Quell Relief,
app users can also gain deeper insight into sleep, thanks to Quell’s
advanced sleep tracking capabilities, which are unique within the
wearables category.
"One of the most common requests of Quell users was to be able to
discreetly manage therapy from their smartphone," said Shai Gozani,
M.D., Ph.D., President and CEO of NeuroMetrix. "We are delighted to
empower Quell users to regain even more control and insight into their
pain management regimen through continued innovation including
smartphone control and advanced sleep tracking. Quell continues to make
a meaningful difference for people with chronic pain.”
Quell is designed for millions of people suffering from chronic pain.
The latest version of Quell gives users the option to start, stop, and
adjust therapy discreetly via their smartphone. It also enables advanced
sleep tracking that provides feedback on eight dimensions of sleep
including sleep duration, quality, body position, time out of bed, and
repetitive leg movements throughout the night. Additional enhancements
include extending battery life by up to 25% and the ability to review
historical trends in various time increments. NeuroMetrix will announce
details of an upgrade program for current Quell users in April 2016.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005236/en/
Copyright Business Wire 2016